Old Web
English
Sign In
Acemap
>
authorDetail
>
Andrew Zolopa
Andrew Zolopa
Research Triangle Park
Dolutegravir
Integrase strand transfer inhibitor
Virology
Nucleoside Reverse Transcriptase Inhibitor
Biology
4
Papers
12
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV.
2021
AIDS
Charlotte-Paige Rolle
Mezgebe Berhe
Tulika Singh
Roberto Ortiz
Anson K. Wurapa
Moti Ramgopal
Peter A. Leone
Jessica E. Matthews
Marybeth Dalessandro
Mark R. Underwood
Konstantinos Angelis
Brian Wynne
Deanna Merrill
Christopher Nguyen
Jean van Wyk
Andrew Zolopa
Show All
Source
Cite
Save
Citations (0)
943. Older Gay Black Men Living with HIV Report Higher Quality of Life than Older Gay White Men, Despite Facing Additional Burdens
2020
Open Forum Infectious Diseases
Peter Mazonson
Theoren Loo
Jeff Berko
Oluwatoyin Adeyemi
Alan Oglesby
Frank Spinelli
Andrew Zolopa
Show All
Source
Cite
Save
Citations (0)
Short Communication: Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor-Naive Patients with Nucleoside Reverse Transcriptase Inhibitor Resistance.
2018
AIDS Research and Human Retroviruses
James F. Demarest
Mark R. Underwood
Marty St. Clair
David Dorey
Dannae Brown
Andrew Zolopa
Show All
Source
Cite
Save
Citations (8)
Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor–Naive Patients With Nucleoside Reverse Transcriptase Inhibitor Resistance
2018
AIDS Research and Human Retroviruses
James Demarest
Mark R. Underwood
Marty St. Clair
David Dorey
Dannae Brown
Andrew Zolopa
Show All
Source
Cite
Save
Citations (4)
1